Brief: Seelos Therapeutics Announces Data Demonstrating Downregulation Of Alpha Synuclein In An In Vivo Gene Therapy Study Of SLS-004 Utilizing CRISPR-dCas9 In Parkinson's Disease
15/12/2022 14:32
Dec 15 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES DATA DEMONSTRATING
DOWNREGULATION
OF ALPHA SYNUCLEIN IN AN IN VIVO GENE THERAPY STUDY OF SLS-004
UTILIZING CRISPR-DCAS9 IN PARKINSON'S DISEASE
* SEELOS THERAPEUTICS INC- SINGLE DOSE OF SLS-004 PRODUCED
SUBSTANTIAL INCREASE IN RECOVERY OF TYROSINE
HYDROXYLASE-POSITIVE (TH+) DOPAMINERGIC NEURONS
Source text for Eikon: ID:nPn9YnFTma
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio